---
title: "VICI: Q2 2026 delivered robust earnings, portfolio growth, and raised AFFO guidance for the year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294263860.md"
description: "Q2 2026 saw strong financial performance with $526.5M net income and $1.06B in revenue, supported by a diversified, fully occupied portfolio and major new investments. AFFO guidance for 2026 was raised to $2.675B–$2.695B, with robust liquidity and investment grade credit ratings.Original document: VICI Properties Inc. [VICI] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-29T21:15:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294263860.md)
  - [en](https://longbridge.com/en/news/294263860.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294263860.md)
generator: "portal-rs"
---

# VICI: Q2 2026 delivered robust earnings, portfolio growth, and raised AFFO guidance for the year

Q2 2026 saw strong financial performance with $526.5M net income and $1.06B in revenue, supported by a diversified, fully occupied portfolio and major new investments. AFFO guidance for 2026 was raised to $2.675B–$2.695B, with robust liquidity and investment grade credit ratings.

Original document: VICI Properties Inc. \[VICI\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VICI.US](https://longbridge.com/en/quote/VICI.US.md)

## Related News & Research

- [VICI Properties Completes $1.75 Billion Senior Notes Offering](https://longbridge.com/en/news/295976207.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [TLC: Resilient cash flow and a 40-year licence extension underpin stable dividends amid lower earnings](https://longbridge.com/en/news/296277922.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**